Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer
Synergistic combinations of gemcitabine with P276-00 or P1446A and their use in the treatment of cancer are disclosed. The invention further describes novel and unique gene signatures comprising gene markers used to monitor the drug response in a subject treated with the said combinations.
1 . A gene signature comprising at least two drug response markers for monitoring drug response in a cancer patient administered with a combination of Gemcitabine and P276-00.
2 . The gene signature of claim 1 , wherein the drug response markers are selected from the group consisting of SNX7, FA38A, DNAI1, RRM2, CDK8, DLG5, FGF5, MKKS, HELLS, PPIL4, SLC19A2, ID1, DICER1, TMPRSS3 and HIST1H2BO, BAX, Cytochrome C, Caspase-3, pAKT, pRB, CyclinD1, MMP-1, VEGF, CDC25B, P21, P14ARF and PTN.
3 . The gene signature of claim 2 , wherein the drug response markers SNX7, FA38A, DNAI1, BAX, Cytochrome C and Caspase-3 are up regulated in the cancer patient administered with the combination of Gemcitabine and P276-00.
4 . The gene signature of claim 2 , wherein the drug response markers RRM2, CDK8, DLG5, FGF5, MKKS, HELLS, PPIL4, SLC19A2, ID1, DICER1, TMPRSS3, HIST1H2BO, pAKT, pRB, CyclinD1, MMP-1, VEGF, CDC25B, P21, P14ARF and PTN are down regulated in the cancer patient administered with the combination of Gemcitabine and P276-00.
5 . A gene signature comprising at least two drug response markers for monitoring drug response in a cancer patient administered with a combination of Gemcitabine and P1446A.
6 . The gene signature of claim 5 , wherein the drug response markers are selected from the group consisting of P21, REV3L, FGF5, PTK7, POLH, P27 and SSTR2.
7 . The gene signature of claim 5 , wherein the markers P21, REV3L, FGF5, PTK7, POLH, P27 and SSTR2 are up regulated in the cancer patient administered with the combination of Gemcitabine and P1446A.
8 . A method of monitoring drug response in a patient suffering from cancer treated with a combination of Gemcitabine and P276-00, comprising detection of a gene signature with at least two drug response markers.
9 . The method of claim 8 , wherein the drug response markers are selected from the group consisting of SNX7, FA38A, DNAI1, RRM2, CDK8, DLG5, FGF5, MKKS, HELLS, PPIL4, SLC19A2, ID1, DICER1, TMPRSS3, HIST1H2BO, BAX, Cytochrome C, Caspase-3, pAKT, pRB, CyclinD1, MMP-1, VEGF, CDC25B, P21, P14ARF and PTN.
10 . A method of monitoring drug response in a patient suffering from cancer treated with a combination of Gemcitabine and P1446A, comprising detection of a gene signature with at least two drug response markers.
11 . The method of claim 10 , wherein the drug response markers are selected from the group consisting of P21, REV3L, FGF5, PTK7, POLH, P27 and SSTR2.